Research progress in immune checkpoint inhibitors treatment of advanced biliary tract cancer
10.3760/cma.j.cn115610-20230616-00290
- VernacularTitle:晚期胆道恶性肿瘤免疫检查点抑制剂治疗研究进展
- Author:
Xinmu ZHANG
1
;
Cong NING
;
Haitao ZHAO
Author Information
1. 中国医学科学院北京协和医院肝脏外科，北京 100730
- Keywords:
Biliary tract neoplasms;
Immune checkpoint inhibitors;
Programmed death-1;
Programmed death-ligand 1;
Progress
- From:
Chinese Journal of Digestive Surgery
2023;22(7):858-865
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancer is a highly lethal disease composed of diverse epithelial tumors, of which incidence is increasing. Nearly two-thirds of patients with biliary tract cancer are in local advanced stage or metastasized at diagnosis. Systemic therapies are the primary treat-ment options, but the prognosis is poor. In recent years, the emergence of immune checkpoint inhibitors has changed the treatment prospects for advanced solid tumors, and multiple clinical trials and related studies have been conducted worldwide. Based on clinical experiences and pertinent researches in the field, the authors expound upon the research progress in immune checkpoint inhibitors treatment of advanced biliary tract cancer.
